|
mutLBSgeneDB |
| |
| |
| |
| |
| |
| |
|
| Gene summary for MAP3K9 |
 Gene summary |
| Basic gene Info. | Gene symbol | MAP3K9 |
| Gene name | mitogen-activated protein kinase kinase kinase 9 | |
| Synonyms | MEKK9|MLK1|PRKE1 | |
| Cytomap | UCSC genome browser: 14q24.2 | |
| Type of gene | protein-coding | |
| RefGenes | NM_001284230.1, NM_001284231.1,NM_001284232.1,NM_033141.3, | |
| Description | mixed lineage kinase 1 (tyr and ser/thr specificity) | |
| Modification date | 20141207 | |
| dbXrefs | MIM : 600136 | |
| HGNC : HGNC | ||
| Ensembl : ENSG00000006432 | ||
| HPRD : 15965 | ||
| Vega : OTTHUMG00000171249 | ||
| Protein | UniProt: P80192 go to UniProt's Cross Reference DB Table | |
| Expression | CleanEX: HS_MAP3K9 | |
| BioGPS: 4293 | ||
| Pathway | NCI Pathway Interaction Database: MAP3K9 | |
| KEGG: MAP3K9 | ||
| REACTOME: MAP3K9 | ||
| Pathway Commons: MAP3K9 | ||
| Context | iHOP: MAP3K9 | |
| ligand binding site mutation search in PubMed: MAP3K9 | ||
| UCL Cancer Institute: MAP3K9 | ||
| Assigned class in mutLBSgeneDB | B: This gene belongs to targetable_mutLBSgenes. | |
| Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
| GO ID | GO Term | PubMed ID | GO:0006468 | protein phosphorylation | 15610029 | GO:0046777 | protein autophosphorylation | 15610029 |
| Top |
| Ligand binding site mutations for MAP3K9 |
| Cancer type specific mutLBS sorted by frequency |
| LBS | AAchange of nsSNV | Cancer type | # samples | A223 | A223T | OV | 1 | V158 | R160C | SKCM | 1 |
| cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma. |
| Top |
| Protein structure related information for MAP3K9 |
| Relative protein structure stability change (ΔΔE) using Mupro 1.1 Mupro score denotes assessment of the effect of mutations on thermodynamic stability. (ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability) |
 : nsSNV at non-LBS : nsSNV at LBS |
 |
| nsSNVs sorted by the relative stability change of protein structure by each mutation Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene. |
| LBS | AAchange of nsSNV | Relative stability change | V158 | R160C | -0.953571 | A223 | A223T | -0.82335076 |
| (MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132) |
| Structure image for MAP3K9 from PDB |
| Top |
| Differential gene expression and gene-gene network for MAP3K9 |
| Differential gene expression between mutated and non-mutated LBS samples in all 16 major cancer types |
| Differential co-expressed gene network based on protein-protein interaction data (CePIN) |
| Top |
| Top |
| Phenotype information for MAP3K9 |
| Gene level disease information (DisGeNet) |
| Disease ID | Disease name | # PubMed | Association type |
| umls:C0025202 | Melanoma | 1 | Biomarker |
| Mutation level pathogenic information (ClinVar annotation) |
| Allele ID | AA change | Clinical significance | Origin | Phenotype IDs |
| Top |
| Pharmacological information for MAP3K9 |
| Gene expression profile of anticancer drug treated cell-lines (CCLE) Heatmap showing the correlation between gene expression and drug response across all the cell-lines. We chose the top 20 among 138 drugs.We used Pearson's correlation coefficient. |
 |
| Gene-centered drug-gene interaction network |
 |
| Drug information targeting mutLBSgene (Approved drugs only) |
| Drug status | DrugBank ID | Name | Type | Drug structure |
| Experimental | DB08703 | 12-(2-hydroxyethyl)-2-(1-methylethoxy)-13,14-dihydronaphtho[2,1-a]pyrrolo[3,4-c]carbazol-5(12H)-one | Small molecule |  |
| Gene-centered ligand-gene interaction network |
 |
| Ligands binding to mutated ligand binding site of MAP3K9 go to BioLip |
| Ligand ID | Ligand short name | Ligand long name | PDB ID | PDB name | mutLBS | VIN | 12-(2-HYDROXYETHYL)-2-(1-METHYLETHOXY)-13,14-DIHYDRONAPHTHO[2,1-A]PYRROLO[3,4-C]CARBAZOL-5(12H)-ONE | 3dtc | A | V158 A223 |
| Top |
| Conservation information for LBS of MAP3K9 |
| Multiple alignments for P80192 in multiple species |
| LBS | AA sequence | # species | Species |
 |
Copyright © 2016-Present - The University of Texas Health Science Center at Houston |